In addition, LncRNA ADAMTS9-AS2 decreased chemoresistance in clear renal cell carcinoma [25], increased temozolomide resistance in glioblastoma [26] and enhanced tamoxifen resistance in breast cancer [27], but no publications reported LncRNA ADAMTS9-AS2 regulated cisplatin resistance in GC cells. This evidence concerns the gene ADAMTS9 and glioblastoma.